[{"orgOrder":0,"company":"Celerion","sponsor":"Celerion","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BBP-711","moa":"2-Hydroxyacid oxidase 1 (HAO1)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Fujifilm Toyama Chemical","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"T-817MA","moa":"Amyloid beta A4 protein (APP)","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Clarus Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2016","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"15","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Veralox Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"VLX-1005","moa":"Arachidonate 12-lipoxygenase, 12R-type (ALOX12B)","graph1":"Hematology","graph2":"Phase II","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"8","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Savara","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Molgramostim","moa":"colony-stimulating factors: granulocyte macrophage colony-stimulating factors (GM-CSF)|colony-stimulating factors: macrophage colony-stimulating factors (M-CSF)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"10","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ALXN2050","moa":"Complement factor B","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Danicopan","moa":"Complement factor D","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"ALXN2080","moa":"Complement factor D (CFD)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"BioLineRx","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Motixafortide","moa":"C-X-C chemokine receptor type 4","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Crescent Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"GMI-1359","moa":"C-X-C chemokine receptor type 4 (CXCR4)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Promentis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"SXC-2023","moa":"Cystine\/glutamate transporter (SLC7A11)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"F2G Limited","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Olorofim","moa":"Dihydroorotate dehydrogenase (quinone), mitochondrial","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"10","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Helsinn Advanced Synthesis","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Pracinostat","moa":"enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Erdafitinib","moa":"Fibroblast growth factor receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"WEX Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Tetrodotoxin","moa":"fluoroquinolone derivatives","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Kashiv BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Exenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Liminal BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Fezagepras","moa":"G-protein coupled receptor 84 | Free fatty acid receptor 1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Madrigal Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Atorvastatin","moa":"HMG-CoA reductase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Madrigal Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Simvastatin","moa":"HMG-CoA reductase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Bioniz Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"BNZ132-1-40","moa":"IL-2 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Bioniz Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"BNZ132-1-40","moa":"IL-2 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Celerion","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Concert Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"CTP-543","moa":"Janus kinase 1 (JAK-1)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Cerecin","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SINGAPORE","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tricaprylin","moa":"Ketone body||Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Cerecin","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SINGAPORE","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tricaprylin","moa":"Ketone body||Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Cerecin","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SINGAPORE","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Tricaprylin","moa":"Ketogenesis (KG)||Ketone body","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Celerion","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Acebilustat","moa":"Leukotriene A4 hydrolase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"8","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Elbasvir","moa":"Nonstructural protein 5A","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Hormone","year":"2014","type":"Inapplicable","leadProduct":"Clomiphene Citrate","moa":"NR3A","graph1":"Endocrinology","graph2":"Phase III","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"10","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Spero Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"PBP","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Omeprazole","moa":"Potassium-transporting ATPase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Omeprazole","moa":"Potassium-transporting ATPase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Oppilan Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"OPL-002","moa":"S1P1 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Crescent Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Uproleselan","moa":"Selectin E","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Neuropore Therapies","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"NPT520-34","moa":"SLC22A8","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Neuropore Therapies","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"NPT520-34","moa":"SLC22A8","graph1":"Neurology","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Galera Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Avasopasem manganese","moa":"SOD","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Amino Acid","year":"2024","type":"Inapplicable","leadProduct":"Levothyroxine Sodium","moa":"Thyroid hormone receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Madrigal Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Resmetirom","moa":"Thyroid hormone receptor beta-1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Acoramidis Hydrochloride","moa":"Transthyretin","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Eidos Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"AG10","moa":"Transthyretin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Arthrosi Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"14-C AR882","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Concert Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Radiolabeled Compound","year":"2019","type":"Inapplicable","leadProduct":"14-C CTP","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Celerion","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Radiolabeled Compound","year":"2017","type":"Inapplicable","leadProduct":"14-C Plazomicin","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Celerion","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"2217LS","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Celerion","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Virus-drug Conjugate","year":"2019","type":"Inapplicable","leadProduct":"Aavlp-Hpv","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Aronora","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"AB002","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"8","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Alexza Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"AZ-010","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Alexza Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AZ-010","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Cerecin","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SINGAPORE","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tricaprylin","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oil","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Enlicitide","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Celerion","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"HIP2B","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"NO-13065","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Celerion","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"PORT-77","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"8","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Pulmatrix","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"PUR118","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Celerion","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"XC130-A10H","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Prometheus Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"PRA023","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Immunology","graph2":"Phase II","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"8","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"PRA023","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"}]
Find Clinical Drug Pipeline Developments & Deals by MTS Health Investors, LLC
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
